Last updated on July 2017

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline a Taxane and Capecitabine


Brief description of study

This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically appropriate or contraindicated for the patient).

Detailed Study Description

This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically appropriate or contraindicated for the patient). In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle. In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel. This study will randomize approximately 350 patients using a 1:1 randomization ratio and stratification based on geographic region, tumor receptor status, and Eastern Cooperative Oncology Group (ECOG) status. At Screening, the Investigator must determine which TPC will be offered to the patient. Data will be collected on subsequent anticancer therapies in both treatment groups from the time patients come off the study treatment until the time of primary data analysis for OS. An independent data monitoring committee (DMC) will assess interim safety and efficacy data.

Clinical Study Identifier: NCT02915744

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Nektar Recruitment

Investigator Site - Tucson
Tucson, AZ United States
  Connect »

Nektar Recruitment

Investigator Site - Orange
Orange, CA United States
  Connect »

Nektar Recruitment

Investigator Site - San Francisco
San Francisco, CA United States
  Connect »

Nektar Recruitment

Investigator Site - Daytona Beach
Daytona Beach, FL United States
  Connect »

Nektar Recruitment

Investigator Site - Miami
Miami, FL United States
  Connect »

Nektar Recruitment

Investigator Site - Plantation
Plantation, FL United States
  Connect »

Nektar Recruitment

Investigator Site - West Palm Beach
West Palm Beach, FL United States
  Connect »

Nektar Recruitment

Investigator Site - Athens
Athens, GA United States
  Connect »

Nektar Recruitment

Investigator Site - Baltimore
Baltimore, MD United States
  Connect »

Nektar Recruitment

Investigator Site - Boston
Boston, MA United States
  Connect »

Nektar Recruitment

Investigator Site - Minneapolis
Minneapolis, MN United States
  Connect »

Nektar Recruitment

Investigator Site - Saint Louis
Saint Louis, MO United States
  Connect »

Nektar Recruitment

Investigator Site - New York
New York, NY United States
  Connect »

Nektar Recruitment

Investigator Site - Chapel Hill
Chapel Hill, NC United States
  Connect »

Nektar Recruitment

Investigator Site - Columbus
Columbus, OH United States
  Connect »

Nektar Recruitment

Investigator Site - Germantown
Germantown, TN United States
  Connect »

Nektar Recruitment

Investigator Site - Nashville
Nashville, TN United States
  Connect »

Nektar Recruitment

Investigator Site - Fort Worth
Fort Worth, TX United States
  Connect »

Nektar Recruitment

Investigator Site - Houston
Houston, TX United States
  Connect »

Nektar Recruitment

Investigator Site - Salt Lake City
Salt Lake City, UT United States
  Connect »

Nektar Recruitment

Investigator Site - Wollongong
Wollongong, Australia
  Connect »

Nektar Recruitment

Investigator Site - Brussels
Brussels, Belgium
  Connect »

Nektar Recruitment

Investigator Site - Charleroi
Charleroi, Belgium
  Connect »

Nektar Recruitment

Investigator Site - Liege
Liège, Belgium
  Connect »

Nektar Recruitment

Investigator Site - Grenoble
Grenoble, France
  Connect »

Nektar Recruitment

Investigator Site - Nimes
Nîmes, France
  Connect »

Nektar Recruitment

Investigator Site - Paris
Paris, France
  Connect »

Nektar Recruitment

Investigator Site - Rouen
Rouen, France
  Connect »

Nektar Recruitment

Investigator Site - Be'er Ya'aqov
Be'er Ya'aqov, Israel
  Connect »

Nektar Recruitment

Investigator Site - Beersheba
Beersheba, Israel
  Connect »

Nektar Recruitment

Investigator Site - Haifa
Haifa, Israel
  Connect »

Nektar Recruitment

Investigator Site - Jerusalem
Jerusalem, Israel
  Connect »

Nektar Recruitment

Investigator Site - Christchurch
Christchurch, New Zealand
  Connect »

Nektar Recruitment

Investigator Site - San Sebasti n
San Sebastián, Spain
  Connect »

Nektar Recruitment

Investigator Site - Barcelona
Barcelona, Spain
  Connect »

Nektar Recruitment

Investigator Site - Madrid
Madrid, Spain
  Connect »

Nektar Recruitment

Investigator Site - Santa Cruz de Tenerife
Santa Cruz de Tenerife, Spain
  Connect »

Nektar Recruitment

Investigator Site - Sevilla
Sevilla, Spain
  Connect »

Nektar Recruitment

Investigator Site - Manchester
Manchester, United Kingdom
  Connect »